Charles Schwab Investment Management Inc. Decreases Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Charles Schwab Investment Management Inc. decreased its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 29.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,224,727 shares of the biopharmaceutical company's stock after selling 941,519 shares during the quarter. Charles Schwab Investment Management Inc. owned about 4.11% of Emergent BioSolutions worth $18,576,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Tidal Investments LLC purchased a new position in shares of Emergent BioSolutions in the 1st quarter worth approximately $34,000. CWM LLC boosted its stake in Emergent BioSolutions by 32,706.7% during the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 4,906 shares during the period. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions during the second quarter valued at $41,000. Price T Rowe Associates Inc. MD raised its stake in shares of Emergent BioSolutions by 22.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 4,409 shares during the period. Finally, Verus Capital Partners LLC bought a new stake in shares of Emergent BioSolutions in the 2nd quarter worth about $68,000. Institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Stock Down 1.5 %

Emergent BioSolutions stock traded down $0.14 during trading hours on Friday, reaching $9.01. The stock had a trading volume of 1,045,164 shares, compared to its average volume of 1,533,003. The company has a market cap of $488.20 million, a price-to-earnings ratio of -2.20 and a beta of 1.59. The business's 50 day moving average price is $9.38 and its 200-day moving average price is $8.57. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Analyst Ratings Changes

Several brokerages have recently weighed in on EBS. Rodman & Renshaw reiterated a "buy" rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Finally, Benchmark lifted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.